Search

Poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitors (PARPi) treatment for ovarian cancer (OC) are ever-changing. This study aimed to compare the efficacy and overall safety of available PARPi as maintenance therapy for BRCA mutation status in patients with newly diagnosed and platinum-sensitive recurrent (PSR) OC patients. Relevant RCTs were systematically retrieved from PubMed and Embase until 31 May 2022. Progression-free survival (PFS) and overall survival (OS) based on BRCA mutation status and adverse events (AEs) regardless of mutation were efficacy and safety endpoints. In newly diagnosed BRCAm-OC patients, olaparib (HR: 0.33; 95% confidence interval [CI]: 0.25, 0.43) and other PARPis [niraparib (HR: 0.40; 95% CI: 0.29, 0.55), rucaparib (HR: 0.40; 95% CI: 0.21, 0.76) and veliparib (HR: 0.44; 95% CI: 0.28, 0.69)] had a statistically significant effect on PFS versus placebo. In BRCAm-PSROC patients, Olaparib exhibited significant benefit (HR: 0.69; 95% CI: 0.54, 0.88) for OS compared to other PARPis. In BRCAwt-PSR OC patients, Olaparib showed a favorable OS benefit than other PARPis (HR: 0.84; 95% CI: 0.57,1.22). Overall, safety profile of all PARPis was acceptable. All PARPis showed significant benefit, with olaparib showing greater benefit in newly diagnosed and PSR OC women. CRD42021288932 [ABSTRACT FROM AUTHOR]

We assembled and annotated the complete mitochondrial genome of Scatoglyphus polytrematus. It is the first complete mitochondrial genome sequence from the genus Scatoglyphus. The mitogenome was 13,966 bp in length and contains 37 genes (including 13 protein-coding genes, 22 transfer RNA (tRNA), and two ribosomal RNA (rRNA)), and one largest non-coding region. The gene arrangement of S. polytrematus is consistent with the pattern of possible common ancestor of astigmatid mites. In the present study, phylogenetic analysis shows that genus Scatoglyphus was clustered into one branch with other Acaridae species. [ABSTRACT FROM AUTHOR]

Highly sensitive determination of proteins is essential to biomedical research and clinical diagnosis. Here a new fluorescence strategy for protein assays is reported that utilizes the exponential amplification reaction and silver nanocluster label-free architecture. Superior sensitivity was obtained for adenosine deaminase with a detection limit of 0.8 milliunit per liter. This method was employed for the determination of adenosine deaminase in human serum. The method displayed high selectivity for adenosine deaminase compared to other proteins, thus providing a promising alternative to standard approaches for the determination of proteins. [ABSTRACT FROM AUTHOR]